These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11348723)

  • 1. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.
    Hodge JW; Grosenbach DW; Rad AN; Giuliano M; Sabzevari H; Schlom J
    Vaccine; 2001 May; 19(25-26):3552-67. PubMed ID: 11348723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).
    Shankar P; Schlom J; Hodge JW
    Vaccine; 2001 Dec; 20(5-6):744-55. PubMed ID: 11738738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
    Hodge JW; Rad AN; Grosenbach DW; Sabzevari H; Yafal AG; Gritz L; Schlom J
    J Natl Cancer Inst; 2000 Aug; 92(15):1228-39. PubMed ID: 10922408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines.
    Schlom J; Sabzevari H; Grosenbach DW; Hodge JW
    Artif Cells Blood Substit Immobil Biotechnol; 2003 May; 31(2):193-228. PubMed ID: 12751840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
    Zhu M; Terasawa H; Gulley J; Panicali D; Arlen P; Schlom J; Tsang KY
    Cancer Res; 2001 May; 61(9):3725-34. PubMed ID: 11325845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors.
    Rad AN; Schlom J; Hodge JW
    Crit Rev Oncol Hematol; 2001; 39(1-2):43-57. PubMed ID: 11418301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells.
    Palena C; Zhu M; Schlom J; Tsang KY
    Blood; 2004 Jul; 104(1):192-9. PubMed ID: 15010371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
    Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
    Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A triad of costimulatory molecules synergize to amplify T-cell activation.
    Hodge JW; Sabzevari H; Yafal AG; Gritz L; Lorenz MG; Schlom J
    Cancer Res; 1999 Nov; 59(22):5800-7. PubMed ID: 10582702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells.
    Yang S; Schlom J
    Cancer Immunol Immunother; 2009 Apr; 58(4):503-15. PubMed ID: 18690438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
    Litzinger MT; Foon KA; Sabzevari H; Tsang KY; Schlom J; Palena C
    Cancer Immunol Immunother; 2009 Jun; 58(6):955-65. PubMed ID: 19009294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.
    Heery CR; Palena C; McMahon S; Donahue RN; Lepone LM; Grenga I; Dirmeier U; Cordes L; Marté J; Dahut W; Singh H; Madan RA; Fernando RI; Hamilton DH; Schlom J; Gulley JL
    Clin Cancer Res; 2017 Nov; 23(22):6833-6845. PubMed ID: 28855356
    [No Abstract]   [Full Text] [Related]  

  • 14. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.
    Briones J; Timmerman JM; Panicalli DL; Levy R
    J Natl Cancer Inst; 2003 Apr; 95(7):548-55. PubMed ID: 12671023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
    Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
    Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
    Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
    Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.
    Slavin-Chiorini DC; Catalfamo M; Kudo-Saito C; Hodge JW; Schlom J; Sabzevari H
    Cancer Gene Ther; 2004 Oct; 11(10):665-80. PubMed ID: 15354200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.
    Yang S; Tsang KY; Schlom J
    Clin Cancer Res; 2005 Aug; 11(15):5603-15. PubMed ID: 16061879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.